JP2015522581A5 - - Google Patents

Download PDF

Info

Publication number
JP2015522581A5
JP2015522581A5 JP2015519155A JP2015519155A JP2015522581A5 JP 2015522581 A5 JP2015522581 A5 JP 2015522581A5 JP 2015519155 A JP2015519155 A JP 2015519155A JP 2015519155 A JP2015519155 A JP 2015519155A JP 2015522581 A5 JP2015522581 A5 JP 2015522581A5
Authority
JP
Japan
Prior art keywords
hcmv
membrane protein
protein complex
recombinant nucleic
glycoprotein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015519155A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015522581A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2013/063750 external-priority patent/WO2014005959A1/en
Publication of JP2015522581A publication Critical patent/JP2015522581A/ja
Publication of JP2015522581A5 publication Critical patent/JP2015522581A5/ja
Pending legal-status Critical Current

Links

JP2015519155A 2012-07-06 2013-06-29 サイトメガロウイルスタンパク質の複合体 Pending JP2015522581A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261668975P 2012-07-06 2012-07-06
US61/668,975 2012-07-06
US201361770257P 2013-02-27 2013-02-27
US61/770,257 2013-02-27
PCT/EP2013/063750 WO2014005959A1 (en) 2012-07-06 2013-06-29 Complexes of cytomegalovirus proteins

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2017149179A Division JP2017192400A (ja) 2012-07-06 2017-08-01 サイトメガロウイルスタンパク質の複合体
JP2017149178A Division JP2017192399A (ja) 2012-07-06 2017-08-01 サイトメガロウイルスタンパク質の複合体

Publications (2)

Publication Number Publication Date
JP2015522581A JP2015522581A (ja) 2015-08-06
JP2015522581A5 true JP2015522581A5 (https=) 2016-07-14

Family

ID=48783208

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2015519155A Pending JP2015522581A (ja) 2012-07-06 2013-06-29 サイトメガロウイルスタンパク質の複合体
JP2017149178A Pending JP2017192399A (ja) 2012-07-06 2017-08-01 サイトメガロウイルスタンパク質の複合体
JP2017149179A Pending JP2017192400A (ja) 2012-07-06 2017-08-01 サイトメガロウイルスタンパク質の複合体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2017149178A Pending JP2017192399A (ja) 2012-07-06 2017-08-01 サイトメガロウイルスタンパク質の複合体
JP2017149179A Pending JP2017192400A (ja) 2012-07-06 2017-08-01 サイトメガロウイルスタンパク質の複合体

Country Status (17)

Country Link
US (4) US9683022B2 (https=)
EP (1) EP2869843B1 (https=)
JP (3) JP2015522581A (https=)
KR (1) KR20150031322A (https=)
CN (1) CN104853771A (https=)
AU (1) AU2013286093B2 (https=)
CA (1) CA2878344A1 (https=)
ES (1) ES2753138T3 (https=)
GB (1) GB2513768B (https=)
HK (1) HK1210037A1 (https=)
IL (1) IL236261A0 (https=)
IN (1) IN2014KN02929A (https=)
MX (2) MX378747B (https=)
RU (1) RU2015103891A (https=)
SG (1) SG11201408328VA (https=)
WO (1) WO2014005959A1 (https=)
ZA (1) ZA201409364B (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2753138T3 (es) 2012-07-06 2020-04-07 Glaxosmithkline Biologicals Sa Complejos de proteínas de citomegalovirus
DK2877580T3 (en) 2012-07-27 2019-04-23 Hope City VAT VACCINE TO DELIVER A UL128 COMPLEX AND PREVENT CMV INFECTION
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
CN115058452A (zh) * 2013-12-03 2022-09-16 霍欧奇帕生物科技有限公司 Cmv疫苗
WO2015165480A1 (en) * 2014-04-30 2015-11-05 Institute For Research In Biomedicine Human cytomegalovirus vaccine compositions and method of producing the same
AU2015251221A1 (en) * 2014-04-23 2016-10-27 CARIPLO, Fondazione Human cytomegalovirus vaccine compositions and method of producing the same
US20150322115A1 (en) * 2014-05-08 2015-11-12 Redvax Gmbh Means and methods for treating cmv
EP3015475A1 (en) * 2014-10-31 2016-05-04 Novartis AG Mammalian cells expressing cytomegalovirus antigens
EP3048114A1 (en) 2015-01-22 2016-07-27 Novartis AG Cytomegalovirus antigens and uses thereof
EP3047856A1 (en) * 2015-01-23 2016-07-27 Novartis AG Cmv antigens and uses thereof
EP3347045A4 (en) 2015-09-10 2019-08-28 City of Hope MVA-GH / GL-PC VACCINATED ANTIBODIES FOR NEUTRALIZING THE INFECTIOSITY OF HUMAN CYTOMEGALOVIRUS AND METHOD THEREFOR
EP3364981A4 (en) * 2015-10-22 2019-08-07 ModernaTX, Inc. VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS
JP2019511255A (ja) 2016-01-11 2019-04-25 バーンダリ,インク. マイクロニードル組成物およびそれを使用する方法
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
MA46584A (fr) 2016-10-21 2019-08-28 Modernatx Inc Vaccin contre le cytomégalovirus humain
US11572389B2 (en) * 2017-01-27 2023-02-07 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Vaccine compositions of herpesvirus envelope protein combinations to induce immune response
KR102774312B1 (ko) 2017-04-04 2025-03-05 유니버시티 오브 워싱톤 파라믹소바이러스 및/또는 뉴모바이러스 f 단백질을 표시하는 자가-조립 단백질 나노구조체 및 이의 용도
CA3060019A1 (en) 2017-04-19 2018-10-25 Glaxosmithkline Biologicals Sa Modified cytomegalovirus proteins and stabilized complexes
WO2019020480A1 (en) * 2017-07-24 2019-01-31 INSERM (Institut National de la Santé et de la Recherche Médicale) ANTIBODIES AND PEPTIDES FOR TREATING HCMV RELATED DISEASES
JP7311489B2 (ja) 2017-07-28 2023-07-19 ヤンセン ファッシンズ アンド プリベンション ベーフェー 異種repRNA免疫化のための方法および組成物
KR20250006307A (ko) * 2017-09-13 2025-01-10 사노피 파스퇴르 인간 시토메갈로바이러스 면역원성 조성물
CA3095216A1 (en) 2018-02-28 2019-09-06 University Of Washington Self-asssembling nanostructure vaccines
IL278418B2 (en) 2018-05-04 2024-01-01 Spybiotech Ltd Vaccine composition
CA3116175A1 (en) * 2018-10-17 2020-04-23 Glaxosmithkline Biologicals Sa Modified cytomegalovirus proteins and stabilized complexes
KR102609106B1 (ko) 2018-12-10 2023-12-05 케이엠 바이올로직스 가부시키가이샤 사이토메갈로바이러스의 선천성 감염을 예방 또는 치료하기 위한 백신
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
EP4004018A1 (en) 2019-07-24 2022-06-01 GlaxoSmithKline Biologicals SA Modified human cytomegalovirus proteins
KR102837045B1 (ko) * 2020-06-09 2025-07-23 케이엠 바이올로직스 가부시키가이샤 사이토메갈로바이러스의 gB와 펜타머의 융합 단백질 및 당해 융합 단백질을 포함하는 백신
TWI810589B (zh) 2020-06-21 2023-08-01 美商輝瑞股份有限公司 人巨細胞病毒糖蛋白B(gB)多肽
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
IL302397A (en) 2020-10-28 2023-06-01 Sanofi Pasteur Liposomes containing a TLR4 agonist, their preparation and uses
JP2024508799A (ja) * 2021-02-24 2024-02-28 ファイザー・インク ヒトサイトメガロウイルス糖タンパク質bポリペプチドにおける新規創薬可能領域およびその使用方法
US20250101067A1 (en) 2022-01-28 2025-03-27 Glaxosmithkline Biologicals Sa Modified human cytomegalovirus proteins

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1201757A3 (en) 1988-12-22 2002-09-11 Genentech, Inc. Method for preparing water soluble polypeptides
EP0463056A1 (en) 1989-03-17 1992-01-02 E.I. Du Pont De Nemours And Company External regulation of gene expression
EP0541721A4 (en) 1990-08-02 1993-12-29 Chiron Corporation Expression of human cmv glycoprotein-h using the baculovirus-insect cell expression system
US5474914A (en) 1992-07-29 1995-12-12 Chiron Corporation Method of producing secreted CMV glycoprotein H
US5362865A (en) 1993-09-02 1994-11-08 Monsanto Company Enhanced expression in plants using non-translated leader sequences
US5693506A (en) 1993-11-16 1997-12-02 The Regents Of The University Of California Process for protein production in plants
US5815900A (en) 1995-03-06 1998-10-06 Matsushita Electric Industrial Co., Ltd. Method of manufacturing a surface acoustic wave module
US20040228842A1 (en) * 2003-02-27 2004-11-18 Shan Lu Compositions and methods for cytomegalovirus treatment
EP3031469B1 (en) 2006-06-07 2023-08-23 The Trustees Of Princeton University Cytomegalovirus surface protein complex for use in vaccines and as a drug target
US7947274B2 (en) * 2007-01-04 2011-05-24 Humabs, LLC. Human cytomegalovirus neutralising antibodies and use thereof
US9439960B2 (en) 2007-10-10 2016-09-13 The Trustees Of Princeton University Cytomegalovirus vaccines and methods of production
ES2443952T3 (es) 2009-09-02 2014-02-21 Novartis Ag Composiciones inmunógenas que incluyen moduladores de la actividad de TLR
WO2011106607A2 (en) * 2010-02-26 2011-09-01 Juvaris Biotherapeutics, Inc. Subunit vaccines for herpes viruses and methods of use
HUE026646T2 (en) 2010-07-06 2016-07-28 Glaxosmithkline Biologicals Sa Preferred liposomes containing lipids of PKA value for delivery of RNA
EP2590625B1 (en) 2010-07-06 2017-09-20 GlaxoSmithKline Biologicals SA Cationic oil-in-water emulsions
WO2012015211A2 (ko) 2010-07-30 2012-02-02 주식회사종근당 사이클로스포린 에이 함유 점안제 조성물
US20130164289A1 (en) * 2010-09-09 2013-06-27 Virginia Commonwealth University Human cytomegalovirus vaccine
JP2013544504A (ja) * 2010-10-11 2013-12-19 ノバルティス アーゲー 抗原送達プラットフォーム
JP6099573B2 (ja) 2011-01-31 2017-03-22 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 新規なヘルペス抗原をコードする核酸分子、それを含むワクチン及びその使用方法
CA2840965C (en) 2011-07-06 2021-03-02 Novartis Ag Cationic oil-in-water emulsions
US11058762B2 (en) 2011-07-06 2021-07-13 Glaxosmithkline Biologicals Sa Immunogenic compositions and uses thereof
EP3508220A1 (en) * 2011-08-31 2019-07-10 GlaxoSmithKline Biologicals S.A. Pegylated liposomes for delivery of immunogen-encoding rna
ES2753138T3 (es) 2012-07-06 2020-04-07 Glaxosmithkline Biologicals Sa Complejos de proteínas de citomegalovirus
EP3015475A1 (en) 2014-10-31 2016-05-04 Novartis AG Mammalian cells expressing cytomegalovirus antigens

Similar Documents

Publication Publication Date Title
JP2015522581A5 (https=)
RU2015103891A (ru) Комплексы белков цитомегаловируса
JP7613685B2 (ja) 新規rsv rna分子及びワクチン接種用組成物
RU2733834C1 (ru) Искусственный ген EctoS_SC2, кодирующий эктодомен гликопротеина S коронавируса SARS-CoV-2 с C-концевым тримеризующим доменом, рекомбинантная плазмида pStem-rVSV-EctoS_SC2, обеспечивающая экспрессию искусственного гена, и рекомбинантный штамм вируса везикулярного стоматита rVSV-EctoS_SC2, используемый для создания вакцины против коронавируса SARS-CoV-2
RU2457250C2 (ru) Способы и композиции для экспрессии антисмысловой вирусной рнк в клетках собаки
JP2023551982A (ja) マルチシストロン性rnaワクチン及びその使用
KR20070086344A (ko) 탠덤 전사 유닛을 갖는 재조합 인플루엔자 벡터
NZ514132A (en) Stable recombinant influenza viruses free of helper viruses
JP2021511318A (ja) 組換えレプリコン系を使用する免疫応答の誘導および増強
JP2011182797A5 (https=)
JP2019530466A5 (https=)
JP2010530245A5 (https=)
JP2017522907A5 (https=)
CN118086288B (zh) 多顺反子的自放大rna及制备方法
CN105396143A (zh) 埃博拉病毒特异性的miRNA以及通过miRNA抑制埃博拉病毒的方法
JP2025169275A5 (https=)
JP6944692B2 (ja) ボルナウイルスベクター及びその利用
CN107201370A (zh) 一种dna分子与重组病毒及它们的制备方法和用途
Macnaughton et al. HDV RNA replication: ancient relic or primer?
CN102286465B (zh) 一种抑制口蹄疫病毒增殖的猪ifitm3基因及构建方法和应用
CN103966259B (zh) 一种基于J亚群禽白血病病毒gag基因保守序列的siRNA重组干扰载体及其制备方法和应用
CN119144620B (zh) 呼吸道合胞病毒mRNA疫苗及其制备方法和应用
CN113876809B (zh) 一种表达TgMIF蛋白的巨噬细胞在制备治疗肝纤维化药物中的应用
CN121941507A (zh) 联合rna疫苗
AU2024269492A1 (en) Vaccine compositions